Superluminal Medicines vs Warby Parker

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 17)
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile
Warby Parker logo

Warby Parker

UnknownFashion & Apparel

General

NYSE-listed (WRBY) DTC eyewear brand with $669M revenue and 240+ stores; vertical integration enabling $95-195 glasses competing with LensCrafters while pursuing profitability path after 2021 IPO.

AI VisibilityBeta
Overall Score
D17
Category Rank
#405 of 1158
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
27
Perplexity
19
Gemini
26

About

Warby Parker is a New York-based direct-to-consumer eyewear company that disrupted the traditional optical retail industry by designing, manufacturing, and selling prescription glasses and sunglasses directly to consumers at $95-$195 price points — compared to $300-500 at traditional optical retailers that added brand markups, optician markups, and optical shop overhead. Listed on NYSE (NYSE: WRBY), Warby Parker generated $669 million in net revenue in fiscal year 2023 and operates 240+ retail stores across the US and Canada alongside its e-commerce and home try-on program.

Full profile

AI Visibility Head-to-Head

86
Overall Score
17
#85
Category Rank
#405
59
AI Consensus
80
stable
Trend
stable
83
ChatGPT
27
80
Perplexity
19
93
Gemini
26
83
Claude
23
95
Grok
26

Key Details

Category
General
General
Tier
Leader
Unknown
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.